PharmaJet receives 2017 Innovation Award in Biosciences

Thursday, May 11, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

Needle-free technology recognized for fight against Polio

GOLDEN, Colo., May 11, 2017 /PRNewswire/ -- PharmaJet® Inc., the maker of needle-free injection

technology, announced today that it received the 2017 Innovation Award in Biosciences.  The award, part of the Colorado Manufacturing Awards, recognized the company for their innovation in manufacturing and teamwork, particularly in their participation in the effort to eradicate Polio.

Polio is a crippling and potentially fatal infectious disease, mainly affecting children under five years old, and there is no cure. As part of its Global Polio Eradication Initiative (GPEI), the World Health Organization has been working closely with PATH and the Gates Foundation to clinically evaluate delivery technologies including the PharmaJet Tropis®, to accommodate increases in demand and vaccine supply shortages.1  Fractional dose polio vaccine delivery has been endorsed by the WHO and the Indian Ministry of Health, as it provides a more cost effective option that will enable routine immunization to more children.

"We're right on the verge of eliminating polio from mankind," said Ron Lowy, Chairman and Chief Executive Officer, PharmaJet Inc.  "A shortage of vaccine is a big hurdle, but PharmaJet can help rectify that with its needle-free technology.  We invented a device that gets the same immune responses with 60 percent less vaccine." 

Refer to Instructions for Use to ensure safe injections and to review risks.

1 To help end polio, intradermal delivery takes center stage, Vaccine and Pharmaceutical Technologies News and Updates – PATH, May 2016, http://www.path.org/newsletters/vaccine-technologies-newsletter.php

About PharmaJet

Based in Golden, Colorado, PharmaJet's mission is worldwide acceptance of PharmaJet needle-free devices as a standard of care in the vaccine delivery market.  PharmaJet's devices are also integral in the development of multiple novel pharmaceuticals.  The innovative Stratis® device has U.S. FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously.  In August 2014, the PharmaJet Stratis® device was cleared for delivery of an influenza vaccine to deliver needle-free flu shots.  The Tropis® device for intradermal injections received authorization to apply the CE Mark in May 2016.  The PharmaJet Needle-free devices are safe, fast and easy-to-use.  They eliminate needlestick injuries, needle reuse and cross contamination, and help reduce sharps waste disposal.  For more information, visit www.pharmajet.com.

CONTACT:Nancy Lillie[email protected] 1-888-900-4321 Option 3

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pharmajet-receives-2017-innovation-award-in-biosciences-300454335.html

SOURCE PharmaJet



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook